PNPL:OTC-Pineapple Express (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 0.1439

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
JDHIF JD Health International Inc

N/A

USD 10.00B
ALBHF Alibaba Health Information Tec..

-0.01 (-3.26%)

USD 8.29B
RADLY Raia Drogasil SA ADR

-0.10 (-2.67%)

USD 7.12B
CLCGY Clicks Group Ltd

-0.23 (-0.58%)

USD 5.27B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

-15.17 (-38.86%)

USD 0.46B
RLLVF Relevium Technologies Inc

N/A

USD 5.33M

ETFs Containing PNPL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.16% 73% C 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.16% 73% C 39% F
Trailing 12 Months  
Capital Gain -19.16% 73% C 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.16% 73% C 39% F
Trailing 5 Years  
Capital Gain -88.93% 43% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -88.93% 43% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 576.29% 96% N/A 93% A
Dividend Return 576.29% 96% N/A 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,975.03% 4% F 8% B-
Risk Adjusted Return 29.18% 79% B- 65% D
Market Capitalization 0.01B 55% F 40% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.